Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-15,896
Closed -$1.81M 223
2024
Q3
$1.81M Sell
15,896
-987
-6% -$117K 0.33% 63
2024
Q2
$2.09M Buy
16,883
+10,107
+149% +$1.3M 0.4% 57
2024
Q1
$894K Sell
6,776
-10,047
-60% -$1.24M 0.2% 117
2023
Q4
$1.83M Sell
16,823
-38
-0.2% -$3.94K 0.39% 56
2023
Q3
$1.74M Buy
16,861
+259
+2% +$27.9K 0.43% 54
2023
Q2
$1.92M Sell
16,602
-543
-3% -$61.7K 0.47% 50
2023
Q1
$1.82M Buy
17,145
+167
+1% +$18K 0.46% 52
2022
Q4
$1.88M Buy
16,978
+323
+2% +$33K 0.56% 47
2022
Q3
$1.43M Buy
16,655
+356
+2% +$31.8K 0.75% 35
2022
Q2
$1.49M Sell
16,299
-391
-2% -$34.7K 0.54% 45
2022
Q1
$1.37M Sell
16,690
-61
-0.4% -$4.81K 0.53% 44
2021
Q4
$1.28M Buy
+16,751
New +$1.33M 0.5% 48

Other funds holding MRK

Eagle Strategies's MRK Position: Q4 2024 in Review

Eagle Strategies sold out of Merck (MRK) in Q4 2024, closing a stake of 15,896 shares — an estimated $1.81M sold.

Eagle Strategies first reported a position in MRK in Q4 2021 and held it in 12 quarters. The position peaked at $2.09M in Q2 2024. 3,608 funds tracked by Wall St. Rank hold MRK as of Q4 2024.

  • Eagle Strategies reported no remaining Merck position as of Q4 2024 after selling out during the quarter.
  • Eagle Strategies sold 15,896 Merck shares in Q4 2024, an estimated $1.81M.
  • Eagle Strategies first reported a position in Merck in Q4 2021 and held it in 12 quarters.
  • Eagle Strategies's Merck position peaked at $2.09M in Q2 2024.
  • 3,608 funds tracked by Wall St. Rank held Merck as of Q4 2024.

Based on Eagle Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.